Literature DB >> 22573314

[The variable spectrum of cutaneous Lyme borreliosis. Diagnosis and therapy].

H Hofmann1.   

Abstract

Lyme borreliosis can affect almost all human organs. Erythema migrans is the first and most frequent manifestation in 80-90% of patients in the early stage of localized skin infection. Besides the typical clinical appearance, many atypical variants can be observed. The solitary borrelial lymphocytoma is much less common and occurs mostly in children. Due to improvement in the early recognition of Lyme borreliosis, the diagnosis is made in the disseminated and late stage in only 10-20% of patients. Multiple erythemata migrantia indicating the hematogenous dissemination of B. burgdorferi remain frequently unrecognized. Late stages of infection feature chronic plasma-cell rich cutaneous inflammation and acrodermatitis chronica atrophicans in its edematous to atrophic forms. Cultivation or DNA detection of B. burgdorferi in skin biopsies are options to prove unusual skin manifestations. Serological detection of Borrelia-specific IgG- and IgM antibodies should be performed according to the two step protocol with ELISA and immunoassay according to the criteria of the MIQ 12. Serological tests have limited utility for follow-up. Antibiotic therapy is very effective if performed according to evidence-based protocols, such as the AWMF guidelines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22573314     DOI: 10.1007/s00105-011-2256-0

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  25 in total

1.  Acrodermatitis chronica atrophicans in two children.

Authors:  Christian Andres; Mahzad Ziai; Harald Bruckbauer; Johannes Ring; Heidelore Hofmann
Journal:  Int J Dermatol       Date:  2010-02       Impact factor: 2.736

Review 2.  A critical appraisal of "chronic Lyme disease".

Authors:  Henry M Feder; Barbara J B Johnson; Susan O'Connell; Eugene D Shapiro; Allen C Steere; Gary P Wormser; W A Agger; H Artsob; P Auwaerter; J S Dumler; J S Bakken; L K Bockenstedt; J Green; R J Dattwyler; J Munoz; R B Nadelman; I Schwartz; T Draper; E McSweegan; J J Halperin; M S Klempner; P J Krause; P Mead; M Morshed; R Porwancher; J D Radolf; R P Smith; S Sood; A Weinstein; S J Wong; L Zemel
Journal:  N Engl J Med       Date:  2007-10-04       Impact factor: 91.245

Review 3.  Is morphoea caused by Borrelia burgdorferi? A review.

Authors:  B Weide; T Walz; C Garbe
Journal:  Br J Dermatol       Date:  2000-04       Impact factor: 9.302

4.  Antialarmin effect of tick saliva during the transmission of Lyme disease.

Authors:  Claire Marchal; Frederic Schramm; Aurélie Kern; Benjamin J Luft; Xiaohua Yang; Tim J Schuijt; Tim Schuijt; Joppe W Hovius; Joppe Hovius; Benoît Jaulhac; Nathalie Boulanger
Journal:  Infect Immun       Date:  2010-12-06       Impact factor: 3.441

Review 5.  Lyme borreliosis.

Authors:  Gerold Stanek; Gary P Wormser; Jeremy Gray; Franc Strle
Journal:  Lancet       Date:  2011-09-06       Impact factor: 79.321

Review 6.  [Lyme borreliosis. Cutaneous manifestation].

Authors:  H Hofmann
Journal:  Hautarzt       Date:  2005-08       Impact factor: 0.751

7.  Diagnostic value of PCR for detection of Borrelia burgdorferi in skin biopsy and urine samples from patients with skin borreliosis.

Authors:  S Brettschneider; H Bruckbauer; N Klugbauer; H Hofmann
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

8.  Epidemiological aspects and molecular characterization of Borrelia burgdorferi s.l. from southern Germany with special respect to the new species Borrelia spielmanii sp. nov.

Authors:  Volker Fingerle; Ulrike C Schulte-Spechtel; Eva Ruzic-Sabljic; Sarah Leonhard; Heidelore Hofmann; Klaus Weber; Kurt Pfister; Franc Strle; Bettina Wilske
Journal:  Int J Med Microbiol       Date:  2007-07-05       Impact factor: 3.473

9.  An epidemiologic study of Lyme disease in southern Sweden.

Authors:  J Berglund; R Eitrem; K Ornstein; A Lindberg; A Ringér; H Elmrud; M Carlsson; A Runehagen; C Svanborg; R Norrby
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Borrelia burgdorferi-associated lymphocytoma cutis: clinicopathologic, immunophenotypic, and molecular study of 106 cases.

Authors:  Claudia Colli; Bernd Leinweber; Robert Müllegger; Andreas Chott; Helmut Kerl; Lorenzo Cerroni
Journal:  J Cutan Pathol       Date:  2004-03       Impact factor: 1.587

View more
  6 in total

Review 1.  [Leg discoloration].

Authors:  L Unger; U Wollina; J Machetanz; C Stelzner; S Schellong
Journal:  Internist (Berl)       Date:  2013-11       Impact factor: 0.743

Review 2.  Efficacy and Safety of Antibiotic Therapy in Early Cutaneous Lyme Borreliosis: A Network Meta-analysis.

Authors:  Gabriel Torbahn; Heidelore Hofmann; Gerta Rücker; Karin Bischoff; Michael H Freitag; Rick Dersch; Volker Fingerle; Edith Motschall; Joerg J Meerpohl; Christine Schmucker
Journal:  JAMA Dermatol       Date:  2018-11-01       Impact factor: 10.282

Review 3.  [Skin biopsy of inflammatory skin diseases in childhood-when is it reasonable?]

Authors:  A Böer-Auer; R Fölster-Holst
Journal:  Hautarzt       Date:  2018-07       Impact factor: 0.751

4.  [Multiple erythema migrans and facial nerve paralysis: clinical manifestations of early disseminated Lyme borreliosis].

Authors:  S A Braun; A M Baran; C Boettcher; B C Kieseier; J Reifenberger
Journal:  Hautarzt       Date:  2014-04       Impact factor: 0.751

5.  Cutaneous Lyme borreliosis: Guideline of the German Dermatology Society.

Authors:  Heidelore Hofmann; Volker Fingerle; Klaus-Peter Hunfeld; Hans-Iko Huppertz; Andreas Krause; Sebastian Rauer; Bernhard Ruf
Journal:  Ger Med Sci       Date:  2017-09-05

6.  Efficacy and safety of pharmacological agents in the treatment of erythema migrans in early Lyme borreliosis-systematic review protocol.

Authors:  Gabriel Torbahn; Heidelore Hofmann; Roman Allert; Michael H Freitag; Rick Dersch; Volker Fingerle; Harriet Sommer; Edith Motschall; Jörg J Meerpohl; Christine Schmucker
Journal:  Syst Rev       Date:  2016-05-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.